findmyKOL

Rebecca Wells, MD

Basic profile

Neurology

ORCIDNone on fileNPI
RegionWinston Salem, NC · SoutheastSpecialtyNeurologyFocusNeurology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationNot yet indexedOnline presenceNot yet checkedPaymentsNone reportedNIH funding2005–2026Why? →

Rebecca Wells is a Neurology physician. ClinicalTrials.gov lists 5 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)

Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →

Clinical & industry

trials, payments and federal funding
5clinical trials

Investigator role on registered studies.

View trials
5NIH grants · 2005–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Medical Center Blvd
Winston Salem, NC 271570001

Telephone

336-716-2255

Registry record last updated 5 Dec 2012.

View the NPPES registry record

Clinical trials

2 more trial records behind the reveal.Reveal →

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    76.7%
    Calcitonin gene-related peptide (CGRP) antagonists30.4%
    Emgality Pen52%Emgality Syringe36%Aimovig Autoinjector12%
    Part D<11 patients
    Serotonin-1b and Serotonin-1d Receptor Agonist17.1%
    Rizatriptan55%Sumatriptan Succinate45%
    Part D<11 patients

    + 4 more classes in this area

  • Musculoskeletal

    5.6%
    Nonsteroidal Anti-inflammatory Drug5.6%
    Indomethacin100%
    Part D<11 patients
  • Cardiovascular

    5.6%
    Calcium channel blocker5.6%
    Verapamil Hcl100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

5 NIH research awards on record, funded 20052026 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”